{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:11:19Z","timestamp":1778724679214,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,13]],"date-time":"2027-03-13T00:00:00Z","timestamp":1804896000000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2314-B-182A-061-MY3"],"award-info":[{"award-number":["112-2314-B-182A-061-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2320-B-182-021"],"award-info":[{"award-number":["113-2320-B-182-021"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["BMRPC17"],"award-info":[{"award-number":["BMRPC17"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1P0151"],"award-info":[{"award-number":["CMRPD1P0151"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC010030"],"award-info":[{"award-number":["ZIA BC010030"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["TCVGH-T1137809"],"award-info":[{"award-number":["TCVGH-T1137809"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmd.2026.100258","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:31:49Z","timestamp":1771716709000},"page":"100258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cells"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2434-3361","authenticated-orcid":false,"given":"Chung-Pu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ching","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Huan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Ho","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh.V.","family":"Ambudkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dmd.2026.100258_bib1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.dmd.2026.100258_bib2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.dmd.2026.100258_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","volume":"596","author":"Gillet","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.dmd.2026.100258_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2026.100258_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.dmd.2026.100258_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101011","article-title":"Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2","volume":"71","author":"Wu","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"9","key":"10.1016\/j.dmd.2026.100258_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discovery"},{"issue":"6","key":"10.1016\/j.dmd.2026.100258_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Schonherr","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.dmd.2026.100258_bib10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/2159-8290.CD-23-0728","article-title":"FGFR inhibition: understanding and overcoming resistance","volume":"13","author":"Tripathi","year":"2023","journal-title":"Cancer Discovery"},{"issue":"3","key":"10.1016\/j.dmd.2026.100258_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00280-008-0908-2","article-title":"Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells","volume":"64","author":"Robey","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100258_bib12","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/1535-7163.MCT-10-0108","article-title":"Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype","volume":"9","author":"Singh","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100258_bib13","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.18632\/oncotarget.13686","article-title":"YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells","volume":"8","author":"Dai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.dmd.2026.100258_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.607275","article-title":"Establishment and characterization of a topotecan resistant non-small cell lung cancer NCI-H460\/TPT10 cell line","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100258_bib15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1021\/acs.jnatprod.9b01022","article-title":"Licochalcone a selectively resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs","volume":"83","author":"Wu","year":"2020","journal-title":"J Natural Products"},{"key":"10.1016\/j.dmd.2026.100258_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114516","article-title":"The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs","volume":"188","author":"Wu","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2026.100258_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117542","article-title":"Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2","volume":"180","author":"Lin","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.dmd.2026.100258_bib18","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1073\/pnas.97.6.2515","article-title":"Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein","volume":"97","author":"Sauna","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib19","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.dmd.2026.100258_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177231","article-title":"Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2","volume":"988","author":"Li","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","article-title":"Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells","volume":"17","author":"Wu","year":"2018","journal-title":"Molecular Cancer"},{"issue":"21","key":"10.1016\/j.dmd.2026.100258_bib22","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1016\/j.bmcl.2012.09.012","article-title":"Downregulation of mdr1 and ABCG2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles","volume":"22","author":"Cuestas","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.dmd.2026.100258_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bcp.2012.12.006","article-title":"The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms","volume":"85","author":"Natarajan","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbamem.2004.11.005","article-title":"Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition","volume":"1668","author":"Ozvegy-Laczka","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dmd.2026.100258_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-319-42934-2_6","article-title":"Gene therapeutic approaches to overcome ABCB1-mediated drug resistance","volume":"209","author":"Lage","year":"2016","journal-title":"Recent Results Cancer Res"},{"issue":"21\u201322","key":"10.1016\/j.dmd.2026.100258_bib27","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","article-title":"Multidrug efflux transporter ABCG2: expression and regulation","volume":"78","author":"Kukal","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100258_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-009-1042-5","article-title":"A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts","volume":"65","author":"Endo","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2026.100258_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.dmd.2026.100258_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.dmd.2026.100258_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmd.2026.100258_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102693","article-title":"Does drug repurposing bridge the gaps in management of Parkinson\u2019s disease? Unravelling the facts and fallacies","volume":"105","author":"Bashir","year":"2025","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.dmd.2026.100258_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100258_bib34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cancers12061366","article-title":"Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:52:57Z","timestamp":1778723577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0090955626000279"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100258","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100258"}}